Status:
RECRUITING
Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG
Lead Sponsor:
National Defense Medical Center, Taiwan
Conditions:
Artificial Intelligence (AI)
Cardiac Implantable Electrical Devices
Eligibility:
All Genders
65-90 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable elect...
Detailed Description
This is a randomized controlled trial designed to evaluate the impact of an AI-ECG strategy on the identification of patients requiring CIEDs. The ECGs of eligible participants will be analyzed by a p...
Eligibility Criteria
Inclusion
- At least one 12-lead ECG within 1 year
Exclusion
- Diagnosis of sick sinus syndrome
- Diagnosis of high-grade or complete atrioventricular block
- Diagnosis of ventricular tachycardia or ventricular fibrillation
- Post CIED implant
- Heart rate below 40 beats per minute by 12-lead ECG
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2026
Estimated Enrollment :
11492 Patients enrolled
Trial Details
Trial ID
NCT07217236
Start Date
November 1 2025
End Date
October 31 2026
Last Update
December 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tri-Service General Hospital
Taipei, Taiwan